Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced positive longer-term results from the open-label, dose-escalating Phase 1b trial of VY-AADC demonstrating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Voyager Therapeutics (VYGR) PT Lowered to $27 at BairdNovember 8, 2018 8:44 AM After-Hours Movers 11/7: (ALAM) (CVNA) (FOSL) Higher; (VYGR) (KRO) (WYNN) Lower (more...)November 7, 2018 5:27 PM Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s DiseaseNovember 7, 2018 4:10 PM